Efficacy and safety of initial treatment (combination immunotherapy or chemotherapy + ICI) in advanced non-small cell lung cancer patients (TPS 1-49%): A multicenter retrospective observational study (TOPGAN2023-01)

Efficacy and safety of initial treatment (combination immunotherapy or chemotherapy + ICI) in advanced non-small cell lung cancer patients (TPS 1-49%): A multicenter retrospective observational study (TOPGAN2023-01) - Efficacy and safety of initial treatment (combination immunotherapy or chemotherapy + ICI) in advanced non-small cell lung cancer patients (TPS 1-49%): A multicenter retrospective observational study (TOPGAN2023-01)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052228

Enrollment

300

Registered

2023-09-18

Start date

2023-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non small cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Pathologically diagnosed as NSCLC (Non-Small Cell Lung Cancer) 2 PD-L1 expression (1-49%) has been confirmed (and TPS is counted) 3 Treatment progress can be collected based on medical records

Exclusion criteria

Exclusion criteria: 1 Positive for genetic mutations (EGFR common mutation/ALK), LCNEC 2 The attending physician has deemed the patient ineligible for registration in this study. 3 Has an active concurrent cancer that affects prognosis

Design outcomes

Primary

Measure	Time frame
1-year survival rate, 2-year survival rate	—

Secondary

Measure	Time frame
PFS OS ORR safety	—

Countries

Japan

Contacts

Public ContactHISASHI TANAKA

Hirosaki University Graduate School of Medicine Department of Respiratory Medicine

xyghx335@gmail.com0172395468

Outcome results